Taysha Gene Therapies Inc (NAS:TSHA)
$ 2.06 -0.09 (-4.19%) Market Cap: 413.83 Mil Enterprise Value: 369.69 Mil PE Ratio: 0 PB Ratio: 7.09 GF Score: 31/100

Q3 2023 Taysha Gene Therapies Inc Earnings Call Transcript

Nov 14, 2023 / 09:30PM GMT
Release Date Price: $1.33
Operator

Good afternoon, and welcome to the Taysha Gene Therapies Third Quarter 2023 Earnings Call. (Operator Instructions) Please note that this call is being recorded.

I'd now like to turn the call over to Hayleigh Collins, the Director, Head of Corporate Communications and Investor Relations. Thank you, and you may proceed,Ă‚ Hayleigh.

Hayleigh Collins
Taysha Gene Therapies, Inc. - Director & Head of Corporate Communications

Thank you. Good afternoon, and welcome to Taysha's third quarter 2023 financial results and corporate update conference call. Earlier today, Taysha issued a press release announcing financial results for the third quarter 2023. A copy of this press release is available on the company's website and through our SEC filings.

Joining me on today's call are Sean Nolan, Taysha's CEO; Suku Nagendran, President and Head of R&D; and Kamran Alam, Chief Financial Officer. We will hold a question-and-answer session following our prepared remarks.

Please note that on today's call, we will be making forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot